Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 03-2021 | |
| Sales | 30,238,240 | 29,419,960 | 29,803,340 | 31,764,150 | 30,059,430 |
| Cost of Goods | 10,429,430 | 9,844,078 | 9,206,133 | 9,850,930 | -9,346,495 |
| Gross Profit | 19,808,800 | 19,575,880 | 20,597,210 | 21,913,220 | 39,405,930 |
| Operating Expenses | 17,548,160 | 18,098,830 | 16,967,590 | 17,812,630 | 15,925,314 |
| Operating Income | 2,261,068 | 1,477,118 | 3,629,737 | 4,101,512 | 4,787,128 |
| Interest Expense | 1,386,429 | 1,516,965 | 1,255,765 | 1,482,802 | 2,337,131 |
| Other Income | 280,915 | 404,105 | 401,694 | 74,172 | 992,612 |
| Pre-tax Income | 1,155,554 | 364,258 | 2,775,666 | 2,692,882 | 3,442,609 |
| Income Tax | 441,811 | -630,701 | 429,585 | 644,405 | -93,398 |
| Net Income Continuous | 713,744 | 994,959 | 2,346,081 | 2,048,477 | 3,536,007 |
| Minority Interests | 1,419 | 897 | 155 | 952 | 1,560 |
| Net Income | $712,325 | $994,062 | $2,345,926 | $2,047,525 | $3,534,447 |
| EPS Basic Total Ops | 0.23 | 0.32 | 0.76 | 0.65 | 1.13 |
| EPS Basic Continuous Ops | 0.23 | 0.32 | 0.76 | 0.66 | 1.13 |
| EPS Diluted Total Ops | 0.22 | 0.31 | 0.75 | 0.65 | 1.12 |
| EPS Diluted Continuous Ops | 0.22 | 0.31 | 0.75 | 0.65 | 1.12 |
| EPS Diluted Before Non-Recurring Items | 1.61 | 1.67 | 2.07 | 1.89 | 1.98 |
| EBITDA(a) | $7,286,286 | $6,500,339 | $8,546,307 | $9,291,565 | $28,741,030 |